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Chronic wound treatment is becoming increasingly difficult and costly, further exacerbated when 
wounds become infected. Bacterial biofilms cause most chronic wound infections and are notoriously 
resistant to antibiotic treatments. The need for new approaches to combat polymicrobial biofilms in 
chronic wounds combined with the growing antimicrobial resistance crisis means that honey is being 
revisited as a treatment option due to its broad-spectrum antimicrobial activity and low propensity 
for bacterial resistance. We assessed four well-characterised New Zealand honeys, quantified for their 
key antibacterial components, methylglyoxal, hydrogen peroxide and sugar, for their capacity to 
prevent and eradicate biofilms produced by the common wound pathogen Pseudomonas aeruginosa. 
We demonstrate that: (1) honey used at substantially lower concentrations compared to those found 
in honey-based wound dressings inhibited P. aeruginosa biofilm formation and significantly reduced 
established biofilms; (2) the anti-biofilm effect of honey was largely driven by its sugar component; (3) 
cells recovered from biofilms treated with sub-inhibitory honey concentrations had slightly increased 
tolerance to honey; and (4) honey used at clinically obtainable concentrations completely eradicated 
established P. aeruginosa biofilms. These results, together with their broad antimicrobial spectrum, 
demonstrate that manuka honey-based wound dressings are a promising treatment for infected chronic 
wounds, including those with P. aeruginosa biofilms.
The management and treatment of chronic wounds is an increasingly difficult and costly problem, further exac-
erbated when the wounds become infected1. Bacterial biofilms, where cells are embedded within a matrix com-
prised of exopolysaccharides and other components including DNA, proteins, and membrane vesicles, are the 
major cause of chronic wound infections and are notoriously resistant to treatment with antibiotics2,3.
Pseudomonas aeruginosa is a particularly virulent wound pathogen and is commonly isolated from the pol-
ymicrobial biofilms found in chronic wounds4–7. Infections caused by P. aeruginosa are especially difficult to 
treat due to the inherent antibiotic resistance mechanisms possessed by the organism. This includes multi-drug 
efflux pumps that remove antibiotics from inside the cell before they can act on specific targets8–10. Additionally, 
the physical structure of the extracellular P. aeruginosa biofilm matrix inhibits penetration of the biofilm, and so 
P. aeruginosa associated chronic wound infections often do not respond to treatments with conventional antibi-
otics11,12. The need for new approaches to combat polymicrobial biofilms in chronic wounds (particularly those 
colonised by P. aeruginosa), combined with the current and growing crisis of antimicrobial resistance warrants 
investigation into the use of complex natural products with antimicrobial activity as potential treatment avenues.
Prior to the introduction of modern antibiotics, treating wounds with honey was a common and effective 
practice, almost certainly due to its potent antimicrobial properties13. Honey is usually made by bees, most com-
monly the European honey bee, Apis mellifera, from the nectar of flowering plants. The honey types derived from 
different plants vary substantially in their antimicrobial activity14–18, which stems from multiple factors including 
high sugar content, low pH and the production of hydrogen peroxide via the bee-derived enzyme, glucose oxi-
dase19,20. Certain honeys derived from the Leptospermum species of plants native to Australia and New Zealand 
(e.g. manuka honey) have an additional antimicrobial component called methylglyoxal, or MGO, which forms 
from the nectar-derived precursor compound, dihydroxyacetone (DHA), during the ripening of honey21–23. The 
level of MGO in Leptospermum honey has been positively correlated to the ‘non-peroxide activity’, referring to 
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the antibacterial activity remaining in honey following neutralisation of hydrogen peroxide via the addition of 
catalase, in previous studies21–23. These honeys are the most commonly used for medical-grade honey products as 
their MGO-derived non-peroxide activity is not affected by catalase present in the body and they are available in 
the form of various sterile products licensed for use in wound care24,25.
The antimicrobial action of New Zealand manuka-based honeys have been demonstrated in vitro against a 
wide range of problematic bacterial pathogens, including those that can colonise the skin and wounds such as 
Staphylococcus aureus and P. aeruginosa26. Of particular note is that manuka honey is equally effective at inhib-
iting multi-drug resistant clinical isolates as it is against sensitive strains, indicating a broad spectrum of activity 
unlike that of other known antibiotics27–29. In addition, bacteria are unable to develop resistance to honey, even 
under conditions that rapidly induce resistance to common antibiotics30,31.
As well as inhibiting planktonic cell growth, honey has previously been demonstrated to have anti-biofilm activ-
ity in vitro. Manuka honey prevents the formation of biofilms by many problematic wound pathogens, includ-
ing Staphylococcus and Streptococcus species, Acinetobacter baumannii, Eschericia coli, Enterobacter cloacae and P. 
aeruginosa, and it eradicates established biofilms32–40. However, the levels of reported anti-biofilm activity are not 
consistent among all studies (ranging from 12–50%), which is likely to be due to differences in the levels of the major 
antibacterial components in the honey. Although MGO has been shown to have inhibitory action against estab-
lished S. aureus and P. aeruginosa biofilms previously41, it is not solely responsible for the anti-biofilm activity of 
manuka-type honeys highlighting the importance of additional components in the honey that modulate activity38.
Here we have assessed the anti-biofilm activity of four New Zealand honeys, including three manuka-based 
samples, and their key antibacterial components (i.e. MGO, hydrogen peroxide and sugar) against two P. aerugi-
nosa strains of different biofilm-forming ability. The honey samples were characterised in terms of their geograph-
ical and floral source and the levels of the two major antibacterial components, MGO and hydrogen peroxide. 
We demonstrate that the honeys are active in both the prevention and eradication of P. aeruginosa biofilms, and 
that MGO is not the major driver of anti-biofilm activity of the manuka-type honeys. While the sugar solution 
(control) was demonstrated to be similarly effective in biofilm prevention and eradication, this does not negate 
the use of honey over sugar solutions in clinical practice as sugar alone is not as effective at similar concentrations 
to honey against other common wound pathogens30,38,42–46. This study also emphasises the importance of using 
well-characterised honeys in order to understand the antimicrobial and anti-biofilm activity and to choose the 
most appropriate honey for treating infected wounds.
Methods
Bacterial strains and growth conditions. The two laboratory reference strains of P. aeruginosa used in 
this study, PAO1 (ATCC 15692) and PA14 (UCBPP-PA14), were originally isolated from burn wounds47,48. Strains 
were grown in cation-adjusted Mueller-Hinton broth (CAMHB; Becton Dickinson Biosciences, USA) at 37 °C.
Honey samples and control solutions. The four honey samples used in this study were all of New 
Zealand (NZ) origin and included three manuka-type honeys: monofloral manuka honey, Medihoney (a 
manuka-based medical-grade honey), and a manuka-kanuka blend, as well as a clover honey. All honey samples 
were supplied by Comvita NZ Ltd (Te Puke, New Zealand). Floral source, harvesting and geographic information, 
as well as the levels of methylglyoxal (MGO) and the MGO pre-cursor compound, di-hydroxyacetone (DHA) 
were supplied by Comvita NZ Ltd and are shown in Table 1. All honey samples were stored in the dark at 4 °C and 
were freshly diluted in CAMHB immediately before use in assays. All honey concentrations are expressed as % 
weight per volume (w/v).
The following control solutions were also included in this study: (i) a sugar solution composed of glucose, 
fructose and sucrose (45 g, 38 g and 1 g, respectively) prepared in water (16 ml) and designed to mimic the con-
centration and composition of the main sugars in honey; (ii) an MGO solution prepared in CAMHB at concen-
trations similar to those present in the manuka-type honeys (i.e. 100 mg/kg, 700 mg/kg, and 900 mg/kg) to assess 
the effects of MGO alone; and (iii) MGO diluted (to the same concentrations as (ii)) in sugar solution to assess the 
combined effects of MGO and the main sugars of honey. MGO was sourced as a ~40% (w/w) solution in water 
(Sigma-Aldrich Co., MO, USA). Control solutions were stored and freshly diluted as per the honey samples above.




Manuka Spring 2010 Hokianga, Northland, NZ Leptospermum scoparium var. incanum 958 4277 0.34
Medihoney Spring 2010 Northland, NZ Leptospermum scoparium var. incanum + Kunzea ericoides 776 883 0.31
Manuka-kanuka Summer 2010/11 Hokianga, Northland, NZ Leptospermum scoparium var. incanum + Kunzea ericoides 161 652 0.68
Clover N/A Balcutha, Otago, NZ Trifolium spp. <10 <20 0.11
Table 1. Harvesting, geographical and composition data for honey samples. aMGO (methylglyoxal) levels 
expressed as mg per kg of honey. bDHA (dihydroxyacetone) levels expressed as mg per kg of honey. DHA 
exhibits no antimicrobial activity itself, but converts to the antimicrobial compound, MGO. DHA levels provide 
an estimate of the potential antimicrobial activity of Leptospermum honey. cH2O2 (hydrogen peroxide) rate of 
production expressed as mmol/h in 1 ml of 10% w/v honey; measured in ten minute intervals over the course of 
40 min. *N/A: not applicable.
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Hydrogen peroxide assay. The levels of hydrogen peroxide (H2O2; another major antimicrobial compo-
nent in honey) produced by the honey samples was determined using an Amplex Red hydrogen peroxide/per-
oxidase kit (Molecular Probes, Life Technologies Corp., Carlsbad, CA, USA) as previously described49, and are 
included in Table 1.
Susceptibility of P. aeruginosa to honeys. The minimum inhibitory concentrations (MICs) of the hon-
eys and sugar solution for P. aeruginosa were determined using the CLSI broth microdilution method50, with 
some modifications described below.
Overnight cultures of P. aeruginosa (2 ml, shaking at 250 rpm) were diluted to give a final cell density of 107 
CFU/ml in fresh CAMHB containing the appropriate test solution (honey or sugar). Honey stock solutions (50% 
w/v) were freshly prepared, and further diluted 2-fold serially in CAMHB to the required test concentrations 
ranging from 1–32%.
Media (CAMHB) alone was included as a growth (untreated) control. The assay was set up in 96-well micr-
otitre plates (BD Falcon, NJ, USA), covered with AeraSeal (Excel Scientific, CA, USA) and incubated for 24 h at 
37 °C in a humidified incubator (Thermo Fisher Scientific, USA). Cell growth was measured by optical density 
at 595 nm (OD595) in a plate reader (VersaMax, Molecular Devices, California, USA) and the MIC was defined 
as the lowest concentration at which the OD was ≤5% relative to the untreated control, indicating at least 95% 
inhibition of cell growth.
Biofilm formation assays. The effect of the test solutions (honey and control solutions) on P. aeruginosa 
biofilm formation was determined using crystal violet static biofilm assays in microtitre plates as previously pub-
lished51, with some modifications.
P. aeruginosa biofilms were prepared in CAMHB with several concentrations of honey, as described above. 
After 24 h incubation at 37 °C, the microtitre plates were washed three times in an automated plate washer 
(Bio-Tek, ELX405, Winooski, VT, USA) with phosphate buffered saline (PBS) to remove unattached cells. The 
plates were stained with 0.2% w/v crystal violet, incubated at room temperature for 1 h and excess crystal violet 
solution washed out using the same program above. The stain that was bound to the adherent biofilm biomass was 
resolubilised in acetic acid (33% w/v, 200 µl), transferred to a new microtitre plate and the OD595 measured. The 
minimum biofilm inhibitory concentration (MBIC) was determined as the lowest concentration at which the OD 
was ≤5% of that of the untreated control, indicating at least 95% inhibition of biofilm formation.
Biofilm elimination assays. P. aeruginosa biofilms were first allowed to form in the wells of mictrotitre 
plates for 24 h at 37 °C as described above, but in CAMHB only (i.e. no treatment). The plates were then washed 
three times with PBS, and various concentrations (0%, 1%, 2%, 4%, 16%, and 32%) of the four honeys and control 
solutions were added to the established biofilms. The wells containing 0% treatment concentration were made 
up to volume using CAMHB. The plates were further incubated for 24 h at 37 °C, and the biofilm biomass was 
quantified using crystal violet as above.
Bacterial cell viability in biofilms. The viability of cells within the P. aeruginosa biofilms following treat-
ment with honey or control solutions (for 24 h, as above) was quantified by the BacTitre Glo Microbial Cell 
Viability Assay Kit (Promega, WI, USA), which measures ATP levels via a luminescence-based luciferase activity 
assay as an indicator of cell viability52,53. After treatment, bacterial biofilms were washed as described above, fol-
lowed by incubation with the BacTitre Glo reagent in CAMHB for 10 min at 37 °C in the dark.
The assay was performed and validity checked against a standard curve as previously described for 
Staphylococcus aureus38, with the modification of using CAMHB for P. aeruginosa biofilms. Biofilms were pro-
duced and washed as above and cells within the biofilm dispersed using a small-probe sonicator (8 sec at 40% 
power; Sonics and materials VC-505) to enable quantification by direct enumeration. Bacterial colony forming 
units (CFUs) per well were calculated and plotted against the luminescent readings from the corresponding well 
to generate the standard curve (Supplementary Fig. S1). The lower detection limit of the BacTitre Glo assay was 
at the luminescence value of <1000, which is equivalent to 103 CFU/ml.
Visualising P. aeruginosa biofilms using confocal laser scanning microscopy (CLSM). P. aeruginosa 
biofilms treated with 1%, 2%, 16%, and 32% of each of the four honeys or the sugar solution control (all prepared 
in CAMHB) were visualised using live/dead staining with Syto9 (Invitrogen, CA, USA) and propidium iodide 
(Becton Dickinson, NJ, USA) and imaged using confocal laser scanning microscopy, as previously described38. As 
higher concentrations of honey are used in the commercially available honey-based wound dressings, higher con-
centrations (64% and 80%) of the monofloral manuka honey and Medihoney samples were also tested.
Susceptibility of P. aeruginosa cells recovered from treated biofilms to honeys. As it is 
known that bacteria are more likely to become resistant to antimicrobial compounds following exposure to 
sub-inhibitory concentrations54,55, the susceptibility of P. aeruginosa following exposure to sub-inhibitory con-
centrations of honey was determined using the MIC and MBIC methods described above. P. aeruginosa cells 
recovered from biofilms treated with sub-inhibitory concentrations (8%) of the manuka-type honeys were tested 
to determine their ability to grow and form biofilms in the presence of higher (previously inhibitory) concentra-
tions of these honeys (16% and 32%).
Statistical analyses. Statistical analyses to compare treatments (honeys and control solutions) were per-
formed using GraphPad Prism (versions 5 and 6). Normal (Gaussian) distribution of data were checked using the 
D’Agostino-Pearson normality test (alpha = 0.05). Differences among honey samples and across control solutions 
were determined using One-Way ANOVA with Tukey Test, with statistical significance set at p < 0.05.
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Results
Effect of honey on P. aeruginosa growth and biofilm formation and re-assessment of suscep-
tibility following honey treatment. The effects of the four NZ honeys and control solutions on P. aerug-
inosa planktonic cell growth and biofilm formation were assessed. The two P. aeruginosa strains used in this 
study, PAO1 and PA14, had different biofilm forming abilities (Supplementary Fig. S2), and all honeys were 
effective at inhibiting the planktonic cell growth and biofilm formation of both strains. Planktonic growth of both 
P. aeruginosa strains was completely inhibited by 16% of the three manuka-type honeys and by 32% clover honey 
(Table 2). The sugar solution also inhibited PAO1 growth at 32%, but PA14 was not inhibited at any of the tested 
sugar concentrations (1–32%).
Biofilm formation was inhibited by the four tested honeys, and the sugar solution for both PAO1 and PA14. 
Generally, the MBICs were the same as the MICs, however the MBIC for PAO1 was 2-fold higher (32%) with 
Medihoney and for PA14 this was 2-fold lower (8%) with manuka honey (Table 2). The MBIC for clover honey 
and the sugar solution was 32%, with the following exceptions: the MBIC for PA14 with clover honey was 16% i.e. 
2-fold less than the MIC; and the MBIC of the sugar solution was 32% while the MIC was >32%.
Table 2 also shows susceptibility testing of P. aeruginosa cells derived from the honey-treated biofilms. 
Generally the MICs and MBICs increased at least 2-fold.
In some cases, low concentrations of manuka and manuka-kanuka honey enhanced biofilm formation (Fig. 1). 
Biofilm biomass of PAO1 was significantly enhanced (p < 0.05) by sub-inhibitory concentrations of manuka (2%) 
and manuka-kanuka (1% and 2%) honey. This effect, which has previously been seen with certain antibiotics, was 
not observed in strain PA14.
Effect of honey on established P. aeruginosa biofilms. As bacterial biofilms are already established 
in chronic wounds, the ability of honey to eradicate pre-formed P. aeruginosa biofilms was investigated. In gen-
eral, treatment with 16% or 32% honey resulted in a significant (p < 0.05) reduction in biofilm biomass (Fig. 2). 
The two strains of P. aeruginosa differed in their responses to the lower concentrations of honey and this may be 
attributed to their different biofilm forming abilities shown in Supplementary Fig. S2 and also indicated by the 
markedly different biomass values at the 0% honey concentration in Fig. 2. For PAO1, the biofilm biomass was 
significantly enhanced when sub-inhibitory concentrations (1–4%) of any of the honeys or the sugar solution 
was used (Fig. 2). Interestingly, the PA14 results showed that at very low levels (1%) of the manuka-kanuka 
honey, Medihoney, clover honey and the sugar control, biofilm biomass was generally inhibited, then augmented 
with higher levels of the treatments until it became inhibitory at the highest levels (Fig. 2). For PAO1 there was 
<40% reduction in biofilm mass following treatment with all honeys except manuka, while all four honeys and 
the sugar solution reduced the biofilms established by strain PA14 by ≥75% relative to the untreated control 
(Supplementary Table S1).
An ATP-based viability assay was used to approximate the number of viable cells remaining within the bio-
film after treatment with the honeys or sugar solution. In general, cell viability decreased significantly for all 
treatments at 32% (Fig. 2 and Supplementary Table S1). While 16% reduced the established biofilm biomass of 
both PAO1 and PA14, cell viability significantly increased (p < 0.05) or there was no change compared to the 
untreated control. Additionally, sub-inhibitory concentrations (1% and 2%) of the different honey or sugar solu-
tion treatments enhanced PA14 cell viability within the established biofilms (p < 0.05) but not the biofilm biomass 
(p > 0.05) (Fig. 2).
The effect of the NZ honeys and the control sugar solution at sub-inhibitory (1% and 2%) and inhibitory (16% 
and 32%) concentrations on established biofilms was further examined using confocal laser scanning micro-
scropy (CLSM) to visualise the biofilms and assess viability within the biofilm (Fig. 3). At concentrations of 16%, 
the total amount of cells was visibly decreased and more dead cells (red; stained with propidium iodide) were 
observed (Fig. 3). At 32%, all treatments caused a substantial visual reduction in the amount of live cell lawn 
(green; stained with Syto9), with fewer live or attached cells at the imaged surface area. These results are consistent 
with the observations in the biofilm eradication assay, where the tested honeys and sugar solution significantly 
decreased the established P. aeruginosa biofilm biomass (Fig. 2 and Supplementary Table S1).
Honey
Initial susceptibilitya
Susceptibility after exposure to 
honeyb
PAO1 PA14 PAO1 PA14
MIC MBIC MIC MBIC MIC MBIC MIC MBIC
Manuka 16 16 16 8 32 32 32 32
Medihoney 16 32 16 16 32 32 32 32
Manuka-kanuka 16 16 16 16 32 32 32 32
Clover 32 32 32 16 N/A N/A N/A N/A
Sugar solution 32 32 >32 32 N/A N/A N/A N/A
Table 2. Concentrations of honey required to inhibit P. aeruginosa cell growth and biofilm formation before 
and after exposure to honey. All concentrations are expressed as percentage weight per volume (% w/v). aInitial 
susceptibility of PAO1 and PA14 to honeys. bSusceptibility of PAO1 and PA14 cells recovered from biofilms that 
had been treated with a sub-inhibitory concentration (8%) of honey. N/A: not applicable as these honeys were 
not tested in resistance assays.
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Higher concentrations (64% and 80%) of the two medical-grade honeys (manuka honey and Medihoney) 
were also tested on established P. aeruginosa biofilms (Fig. 4) to better reflect the clinical situation, where these 
honeys are used at high concentrations as an antibacterial wound treatment. CLSM imaging showed that these 
medical-grade honeys were effective at reducing established P. aeruginosa biofilms, with very few cells remain-
ing on the imaged surface relative to the untreated control (Fig. 4). Visually, there were also fewer fluorescently 
stained cells remaining attached on the imaged surfaces, compared to 32% of the same honey treatment (Figs. 3 
and 4).
Effect of MGO on P. aeruginosa biofilm formation and eradication. Methylglyoxal (MGO) makes 
a substantial contribution to the activity of manuka and related honeys, and has previously been demonstrated 
to be effective at both inhibiting biofilm formation and eradicating established P. aeruginosa biofilms41. To deter-
mine the contribution of MGO to the biofilm prevention and eradication activity of the manuka-type honeys in 
this study, MGO was tested both with and without the addition of the sugar solution at concentrations represent-
ative of those in each of the manuka-type honeys (Table 1).
Figure 1. Effect of honey and sugar solution on P. aeruginosa biofilm formation. P. aeruginosa PAO1 (A) and 
PA14 (B) biofilms were allowed to form in the presence of four NZ honeys (manuka, Medihoney, manuka-
kanuka, or clover) or a sugar solution. Biofilm formation was assessed using a static biofilm formation assay 
with crystal violet staining to quantify biomass. Biofilm formation is expressed as % relative to that produced by 
the untreated control (Control), which is set at 100%. Error bars represent ± SD of three biological samples, all 
performed in triplicate. *Indicates statistically significant difference (p < 0.05) relative to the untreated control 
(Control; 0%).
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Figure 2. Effect of honey or sugar solution on established P. aeruginosa biofilms and on cell viability within the 
biofilms. Established P. aeruginosa PAO1 (left panels) and PA14 (right panels) biofilms were treated with four 
NZ honeys (manuka, Medihoney, manuka-kanuka, and clover), or a sugar solution. Biofilm biomass remaining 
post-treatment (coloured lines) was quantified using crystal violet staining and expressed as OD595 (left y-axis). 
The corresponding cell viability (black line) within remaining biofilms was assessed via ATP production 
using the BacTitre Glo Viability Kit and CFU/well values were determined from a previously established 
standard curve (right y-axis). Data represents mean values from three biological replicates, all performed in 
triplicate ± SD. Coloured (*) indicate statistically significant decrease (p < 0.05) in biofilm biomass and black 
(*) indicates statistically significant difference (p < 0.05) in ATP production, both relative to the control (at 0% 
honey concentration).
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Some reduction in biofilm formation was observed using MGO alone or in combination with sugar (Fig. 5), 
however, the MGO solutions did not reproduce the inhibitory effects observed with the manuka-type honeys 
(Fig. 1). The biggest reduction in biofilm formation was observed when MGO solution, with or without sugar, 
was used at the concentration equivalent to manuka honey, i.e. 900 mg/kg (Fig. 5). Biofilm formation was reduced 
Figure 3. Visualisation of established P. aeruginosa biofilms treated with different honeys. 3-D images 
produced by confocal laser scanning microscopy of established P. aeruginosa PAO1 and PA14 biofilms, 
following treatment with sub-inhibitory (1 and 2%) and inhibitory (16 and 32%) concentrations of NZ honeys 
(manuka, Medihoney, manuka-kanuka, or clover) or control sugar solution. Biofilms were stained with Syto9 
(green = viable cells) and propidium iodine (red = dead cells). Scale bar represents 50 µm.
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by up to 50% when MGO alone was used at a concentration of 16% honey equivalence (Fig. 5). MGO with sugar 
used at a concentration of 32% honey equivalence resulted in a 75% reduction in biofilm formation (Fig. 5). 
In contrast, >95% inhibition was seen with the corresponding honey at the equivalent MGO concentrations 
(Fig. 1). The addition of MGO to the sugar solution also appeared to counteract the inhibitory effect observed for 
the sugar solution alone for biofilm formation (Figs. 1 and 5), and some sub-inhibitory concentrations of MGO 
(alone or in combination with sugar solution) enhanced biofilm formation.
As with the biofilm inhibition assays, treatment with MGO at concentrations similar to those present in the 
manuka-type honeys did not reduce the biofilm biomass to the same degree as the corresponding honey (Figs. 6 
and 2). While there was some reduction in biofilm mass by 32% MGO alone or in combination with sugar (Fig. 6), 
this was markedly less than that of the manuka-type honeys at this concentration (Fig. 2).
Discussion
Chronic wounds harbour bacterial populations that commonly exist as biofilms41, which are known to be far 
more tolerant to antibiotics than planktonic bacteria56,57. Ideally, effective treatments of chronic wounds should 
have broad-spectrum antimicrobial activity effective against multi-drug resistant wound pathogens, as well as 
the ability to reduce or eradicate existing biofilms in the wound, while simultaneously preventing the forma-
tion of new biofilms. The need for new chronic wound treatments coupled with the rise in antibiotic resist-
ance has prompted renewed interest in complex, natural products with antimicrobial activity–like honey, and 
the use of manuka-type honeys for the treatment of chronic wounds is especially promising. Here we show that 
manuka-type honeys have the ability to prevent and eradicate biofilms formed by the common wound pathogen, 
P. aeruginosa, notorious for being recalcitrant to conventional treatments.
The manuka-type honeys tested inhibited P. aeruginosa planktonic cell growth and the formation of biofilms, 
and also eliminated established biofilms at concentrations that could be maintained in wound dressing (8–32%; 
Table 2 and Figs. 1–4). This is in general agreement with the literature as several studies have reported on the 
effectiveness of manuka-type honeys against P. aeruginosa33,34. However, the amount of honey required to inhibit 
P. aeruginosa growth and biofilm formation varies between these studies, which report concentrations of honey 
between 12–50% as being inhibitory. In comparison, the growth and biofilm inhibitory concentration against 
P. aeruginosa in our study was generally at 16% honey. These differences are likely to be due to the different 
strains of P. aeruginosa tested in the studies and their relative biofilm-forming abilities as this is known to vary 
among strains. Differences between specific manuka-type honeys used e.g. the age, floral source, or processing 
and storage conditions of the honey samples can also affect the inhibitory action observed16,58,59. Most studies 
examining the antimicrobial effects of honey do not thoroughly characterise the honeys tested, despite the fact 
that the chemical composition and specifically the concentrations of the major antibacterial components (hydro-
gen peroxide, antimicrobial peptides, phenolics, or MGO) vary from one honey type to another and significantly 
affect the antimicrobial activity20–22,60. This highlights the importance of characterising the honey types tested, for 
example, by determining the levels of their key antibacterial components for ease of comparison between studies 
and for determining the most appropriate honeys for use in the clinic. However, fully characterising honey can be 
Figure 4. Effects of high concentrations of manuka and Medihoney on established P. aeruginosa biofilms. 3-D 
images produced by confocal laser scanning microscopy of established P. aeruginosa PAO1 and PA14 biofilms, 
following treatment with high concentrations (64 and 80%) of manuka honey and Medihoney. Biofilms were 
stained with Syto9 (green = viable cells) and propidium iodine (red = dead cells). Scale bar represents 50 µm.
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very difficult due to its complex nature, and even when done individual components, or combinations of these, 
may not necessarily align to inhibition very well.
MGO is believed to be one of the major antibacterial and anti-biofilm components of manuka honey, with 
demonstrated inhibitory effects against a range of bacteria41. In previous studies, the anti-biofilm activity of 
manuka-type honey against S. aureus and P. aeruginosa has been largely attributed to MGO22,41,61. Under the con-
ditions used here however, MGO treatment at concentrations broadly corresponding to those in the manuka-type 
honeys, tested alone or in the presence of sugar, did not induce similar biofilm inhibitory or eliminatory effects 
(Figs. 5 and 6). This suggests that MGO is not the main driver of the anti-biofilm effects of manuka-type honey. 
Indeed our results indicate that MGO contributes very little to the anti-P. aeruginosa biofilm activity (Figs. 5 
and 6). Although our results do not agree with previous studies, this is likely to be because of the different P. 
aeruginosa strains used and more directly related to the differences in the MGO concentrations tested. Previous 
studies showing successful P. aeruginosa biofilm inhibition by MGO alone have generally used much higher 
concentrations of MGO (between 1800–7300 mg/kg)41 than used here (288 mg/kg, equivalent to 32% manuka 
honey). The high concentrations of MGO used in other studies are well above the highest reported levels of MGO 
in manuka-type honeys (~1100 mg/kg)23,62 and may have toxic effects on host cells63. Our findings suggest that P. 
aeruginosa is markedly more tolerant to MGO than other common wound pathogens, such as S. aureus49, con-
sistent with previous reports41. This is likely to be due to the ability of P. aeruginosa to detoxify MGO in several 
ways via the glyoxylase system (composed of glyoxalase I and II) and P. aeruginosa is known to have three fully 
functional glyoxylase I homologues, whereas most bacteria contain one glyoxylase I gene64.
Under the conditions tested here, sugar alone was generally almost as effective as the honey treatments (Figs. 1 
and 2). However, since wound infections are polymicrobial, and we and others have previously shown that sugar 
is not as effective as manuka-type honeys against other common wound pathogens such as S. aureus38, sugar is 
not likely to be an equal or better option for chronic wound treatment, especially when the added wound healing 
and anti-inflammatory properties of honey13 are taken into account. The contribution of the sugar component 
of honey to the anti-biofilm effects observed here may be due to high osmolarity or to a nutrient effect, such as 
Figure 5. Effect of MGO on biofilm formation by P. aeruginosa. Biofilm formation by P. aeruginosa PAO1 
(A) and PA14 (B) in the presence of MGO and MGO plus sugar solution. MGO concentrations correspond to 
those present in the manuka-type honeys: 100 mg/kg as in manuka-kanuka honey, 700 mg/kg as in Medihoney, 
and 900 mg/kg as in manuka honey. Biofilm formation is expressed as a percentage relative to the untreated 
control, which is set at 100%. Results presented are mean values from three biological replicates, all performed 
in triplicate ± SD.
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through changes to central carbon metabolism. Sugar in honey has been linked to disrupted quorum sensing 
in P. aeruginosa65, and high concentrations of fructose in honey or sugar solutions have been found to prevent 
P. aeruginosa biofilm formation66. It is also possible that P. aeruginosa is sensitive to the sugar solution due to 
its deficit in sugar transporters67. Adding osmotic pressure (e.g. via extra salt or sugar) is known to affect the 
swarming ability of bacteria and defects in swarming coincide with deficiencies in biofilm formation68. So, we 
tested the effect of the honeys and sugar solution on the swarming ability of P. aeruginosa to determine whether 
the anti-biofilm effect could be explained via this mechanism, however our results did not indicate this to be the 
case (Supplementary Table S2). While all the tested honeys and the sugar solution did affect the swarm colony size 
in both PA14 and PAO1, the manuka-type honeys showed marked reduction of the swarm size when used at a 
concentration of 8%, and colony inhibition at 16%, indicating that there are additional components in these hon-
eys contributing to the overall anti-biofilm activity reported here. Future studies investigating how manuka-type 
honeys affect other mechanisms involved in P. aeruginosa biofilm formation (e.g. swimming motility or quorum 
sensing), may help to identify key components in honey responsible for its anti-biofilm action. These components 
could be integrated into wound dressings to test their direct biofilm inhibitory action, as has been done previously 
using the amino acid tryptophan69, which may provide better mechanistic insights.
While low concentrations (up to 32%) of any of the four honeys or the sugar solution were able to significantly 
reduce established P. aeruginosa biofilm biomass, these could not completely remove established biofilm (Fig. 3). 
In clinical practice, the honey concentration in honey-based wound dressings and gels is close to 100%, although 
there can be some dilution of the honey by wound exudate70. When the two medical-grade manuka-type honeys 
were tested at concentrations that better represent the concentrations used in clinical practice (64% and 80%), 
complete removal of established P. aeruginosa biofilms was observed (Fig. 4). Although in vitro studies can only 
provide insight to the in vivo situation, these results warrant further exploration of honey wound dressings for the 
treatment of infected chronic wounds.
Honey is an attractive substitute for topical antibiotics not only due to its broad-spectrum antimicrobial activ-
ity, but also because previous studies show that a range of bacteria capable of colonising the skin and wounds, 
including P. aeruginosa, S. aureus, E. coli and A. calcoaceticus do not develop resistance to honey, including 
medical-grade manuka honey30,31. This low propensity for resistance is likely to be due to the complexity of honey, 
Figure 6. Effect of MGO on established P. aeruginosa biofilms. P. aeruginosa PAO1 (A) and PA14 (B) biofilms 
treated with MGO, with and without sugar solution. MGO concentrations used correspond to those in the 
manuka-type honeys: 100 mg/kg as in manuka-kanuka honey, 700 mg/kg as in MedihoneyM, and 900 mg/kg as 
in manuka honey. Biofilm formation is expressed as a percentage relative to the untreated control, which is set at 
100%. Results presented are mean values from three biological replicates, all performed in triplicate ± SD.
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which acts in a multifactorial way to target cells via several antibacterial compounds30. However, honey resistance 
has only been explored in planktonic cells and not within biofilm cells. Treatment of biofilm-associated chronic 
wounds often requires continued disruption of biofilms, where multiple doses of antibacterial agents over time 
are needed that may eventually induce resistance71. Here we tested biofilm cells recovered from sub-inhibitory 
manuka-type honey treatments for the development of resistance. These biofilm-recovered cells showed a 2-fold 
increase in MIC and MBIC (Table 1), suggesting that P. aeruginosa may acquire tolerance to honey treatment or 
that persister P. aeruginosa cells may develop during continued exposure to honey72. Further work is required to 
determine whether this decreased susceptibility is due to reversible, temporary tolerance or is an acquired state 
of honey resistance.
This study is the first to test a suite of well-characterised New Zealand honeys, and their key antibacterial 
components (sugar and MGO) against two P. aeruginosa strains with different biofilm forming abilities using 
a range of in vitro assays and fluorescent microscopy. We demonstrate that: (1) honey present at relatively low 
concentrations (up to 32%) compared to those used in honey-based wound dressings (~80–100%) inhibited the 
ability of P. aeruginosa to form biofilms and significantly reduced established biofilms; (2) the anti-biofilm effect 
of the manuka-type honeys was largely (but not wholly) driven by the sugar component and not MGO as previ-
ously suggested; (3) cells recovered from biofilms treated with sub-inhibitory concentrations of honey had slightly 
reduced susceptibility to honey; and (4) manuka-type honeys used at clinically obtainable concentrations (64% 
and 80%) completely eradicated established P. aeruginosa biofilms. Taken together, our results show that when 
used at appropriate concentrations, wound dressings saturated with manuka-based honey are promising effective 
treatments for infected chronic wounds, including those containing P. aeruginosa biofilms.
Data availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information files).
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